How to Profit From Every Biotech Buyout

Amgen's acquisition of Onyx underscores the fact that one simple biotech investment may also be the best one. More 

Grab These 3 Short-Term ETF Bargains While They Last

Leadership in the ETF circles has been focused on the regional and larger banks, gold miners, Internet, biotech and restaurant funds. More 

Bull’s Eye Report: Biogen Idec (BIIB)

Biogen Idec (BIIB), along with others in the biotech space, is looking very strong, with momentum that puts it ahead of the pack. More 

Changing U.S. Demographics Mean a Decades-Long Healthcare Boom

The aging of America's boomers is a compelling macro trend at work. And there's no better way to play that trend than via these ETFs. More 

Bull’s Eye Report:Isis Pharmaceuticals (ISIS)

Biotechs are blowing up -- and ISIS Pharmaceuticals (ISIS) is showing an attractive buy right now with potential 12% upside. More 

Bull’s Eye Report: Pharmacyclics (PCYC)

Pharmacyclics (PCYC) is our top pick today as an outperformer in the biotech space. More 

Bull’s Eye Report: Pharmacyclics (PCYC)

Biotech is a hot industry that's extremely volatile right now. Get on the right side of that volatility with Pharmacyclics (PCYC). More